Efficacy of Marine ω-3 Fatty Acid Supplementation vs Placebo in Reducing Incidence of Dry Eye Disease in Healthy US Adults

Authors:
  • VGVITAL Research Group
    VITAL Research Group

Abstract
Dry eye disease (DED) is a multifactorial disease of the ocular surface characterized by a loss of homeostasis of the tear film causing a variety of symptoms and visual impairment.1,2 In the US, an estimated 16.4 million adults have been diagnosed with DED, and an additional 6 million adults have reported DED symptoms without a formal diagnosis.3 The pathophysiology of DED is incompletely understood, but typically involves a cycle of inflammation, including both innate and adaptive immune responses.4-6 Accordingly, management of DED often involves treatment with topical artificial tears plus limited-duration topical steroids; nonglucocorticoid immunomodulatory drugs, such as topical cyclosporine A; or the lymphocyte function–associated antigen (LFA)-1 antagonist lifitegrast.7

This publication has 24 references indexed in Scilit: